Insider Transactions in Q2 2022 at Fate Therapeutics Inc (FATE)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2022
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+50.0%
|
-
|
|
Jun 09
2022
|
Shefali Agarwal |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+45.19%
|
-
|
|
Jun 09
2022
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+46.65%
|
-
|
|
Jun 09
2022
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+44.8%
|
-
|
|
Jun 09
2022
|
Karin Jooss |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+46.76%
|
-
|
|
Jun 09
2022
|
John Mendlein |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+4.93%
|
-
|
|
Jun 09
2022
|
William H Rastetter |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+43.29%
|
-
|
|
Jun 09
2022
|
Yuan Xu |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+39.24%
|
-
|
|
Jun 09
2022
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+43.29%
|
-
|
|
Jun 09
2022
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,650
+0.07%
|
-
|
|
Jun 09
2022
|
Robert S Epstein |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+43.29%
|
-
|
|
Jun 07
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
841
-31.37%
|
$17,661
$21.89 P/Share
|
|
Jun 03
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
807
-30.1%
|
$17,754
$22.8 P/Share
|
|
Jun 03
2022
|
Timothy Coughlin |
SELL
Open market or private sale
|
Direct |
1,439
-2.44%
|
$31,658
$22.81 P/Share
|
|
Jun 03
2022
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
672
-25.07%
|
$14,784
$22.75 P/Share
|
|
Jun 03
2022
|
Karin Jooss |
SELL
Open market or private sale
|
Direct |
1,483
-55.32%
|
$32,626
$22.82 P/Share
|
|
Jun 03
2022
|
John Mendlein |
SELL
Open market or private sale
|
Direct |
1,364
-0.86%
|
$30,008
$22.79 P/Share
|
|
Jun 01
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
25,000
-11.67%
|
$550,000
$22.96 P/Share
|
|
Jun 01
2022
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.45%
|
$150,000
$6.55 P/Share
|
|
Apr 22
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.13%
|
$340,000
$34.85 P/Share
|
|
Apr 22
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.21%
|
$20,000
$2.7 P/Share
|
|
Apr 21
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.65%
|
$1,080,000
$36.23 P/Share
|
|
Apr 21
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.1%
|
$60,000
$2.7 P/Share
|
|
Apr 19
2022
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,062
-2.62%
|
$142,170
$35.37 P/Share
|
|
Apr 01
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
25,000
-11.67%
|
$950,000
$38.85 P/Share
|
|
Apr 01
2022
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.53%
|
$125,000
$5.7 P/Share
|